Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study

Saved in:
Bibliographic Details
Published in:Journal of Asthma and Allergy
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864030191851929604
collection WordPress RSS
FRELIP Feed Integration
container_title Journal of Asthma and Allergy
description
discipline_display Medical & Health Sciences
discipline_facet Medical & Health Sciences
format Online Article
RSS Article
genre Journal Article
id rss_article:35792
institution FRELIP
journal_source_facet Journal of Asthma and Allergy
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
— — — — — Allergology and Immunology
Clinical Medicine
Medical & Health Sciences
sub_discipline_display Clinical Medicine
sub_discipline_facet Clinical Medicine
subject_display — — — — — Allergology and Immunology
Clinical Medicine
Medical & Health Sciences
— — — — — Allergology and Immunology
Clinical Medicine
Medical & Health Sciences
subject_facet — — — — — Allergology and Immunology
Clinical Medicine
Medical & Health Sciences
title Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
title_auth Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
title_full Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
title_fullStr Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
title_full_unstemmed Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
title_short Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
title_sort benralizumab reduces asthma exacerbations and costs among medicare beneficiaries with severe asthma: the zephyr-5 study
topic — — — — — Allergology and Immunology
Clinical Medicine
Medical & Health Sciences
url https://www.dovepress.com/benralizumab-reduces-asthma-exacerbations-and-costs-among-medicare-ben-peer-reviewed-fulltext-article-JAA